Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.

BACKGROUND AND PURPOSE: The phase III EORTC 1219-DAHANCA 29 intergroup trial evaluates the influence of nimorazole in patients with locally advanced head and neck cancer when treated with accelerated radiotherapy (RT) in combination with chemotherapy. This article describes the results of the RT Benchmark Case (BC) performed before patient inclusion. MATERIALS AND METHODS: The participating centers were asked to perform a 2-step BC, consisting of (1) a delineation and (2) a planning exercise according to the protocol guidelines. Submissions were prospectively centrally reviewed and feedback was given to the submitting centers. Sørensen-Dice similarity index (DSI) and the 95th percentile Hausdorff distance (HD) were retrospectively used to evaluate the agreement between the centers and the expert contours. RESULTS: Fifty-four submissions (34 delineation and 20 planning exercises) from 19 centers were reviewed. Nine (47%) centers needed to perform the delineation step twice and three (16%) centers 3 times before receiving an approval. An increase in DSI-value and a decrease in HD, in particular for the prophylactic Clinical Target Volume (pCTV), could be found for the resubmitted cases. No unacceptable variations could be found for the planning exercise. CONCLUSIONS: These BC-results highlight the need for effective and prospective RTQA in clinical trials. Even with clearly defined protocol guidelines, delineation and not planning remain the main reason for unacceptable protocol variations. The introduction of more objective quantitative analysis methods, such as the HD and DSI, in future trials might strengthen the evaluation by experts.

Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort?

BACKGROUND AND PURPOSE: The planning process in radiotherapy (RT) typically involves the acquisition of a unique set of CT images - and eventually of functional images - which is used for delineation of target volumes (TV) and organs at risk (OAR) and for dose calculation. Restricting the delineation and dose calculation solely on pre-treatment images is an oversimplification as it is only a snapshot of the patient's anatomy. The objectives of the present study were (1) to assess the consequences of anatomic modification in dose distribution for both TVs and OARs; (2) to assess the potential benefit of adaptive strategies using Helical Tomotherapy (HT); and (3) to compare CT-based and FDG-PET-based adaptive planning strategies. MATERIALS AND METHODS: Ten patients with H&N SCC were imaged before and during concomitant chemo-RT using CT and FDG-PET acquisition after a mean dose of 14.2, 24.5, 35.0 and 44.9 Gy. Simultaneous integrated boost IMRT planning was performed using HT. We compared (1) the planned dose distribution, (2) the delivered dose distributions that took into account impact of anatomical modifications on dose distribution, (3) the adaptive dose distributions after replanning to take into account the anatomic modifications and the anatomic or functional GTV shrinkage. RESULTS: There was an increase between the planned and the delivered high dose volumes, which correlated with the slope of the GTV shrinkage. The adaptive high dose volumes were significantly smaller than the delivered ones. The difference between the adaptive and the delivered high dose volume also correlated with the slope of the GTV shrinkage. For both parotid glands combined, the delivered D(mean) showed a statistical trend for an increase of 4.4% compared to the planned D(mean). For the ipsilateral parotid glands, there was a correlation between the D(mean) gain and the slope of the GTV shrinkage when an adaptive planning was used. For the oral cavity, the adaptive D(mean) was 10% smaller than the delivered ones. For the PRV around the spinal cord, there was an increase of about 4.5% between the delivered and the planned D(2%). The adaptive planning translated into a decrease in D(2%) of 7.2%. The differences between the delivered and planned D(2%) and between the adaptive and the delivered D(2%) were correlated with the slope of the GTV shrinkage. For the CTV(proph) and PTV(proph) coverage, adaptive strategy induced a better dose conformation. No significant difference was observed in the various figures of merit between PET-based plan and CT-based isodose distributions. CONCLUSIONS: The dose distribution that is actually delivered to patients significantly differs from what was planned because of anatomic modifications. Adaptive multi-modality IMRT is feasible in H&N tumors and could compensate and improve dose distribution. Some useful surrogate criteria or "flags" are, however, needed to identify patients who might benefit from an adaptive strategy. The optimal adaptive strategy still needs to be defined and prospective studies will have to be conducted to address the safety and the clinical impact of such approaches on patient outcome.

Recommendations for a lifestyle which could prevent breast cancer and its relapse: physical activity and dietetic aspects.

External factors such as eating habits and physical activity have an important impact on breast cancer risk. This paper reviews the literature on the relationship between breast cancer and lifestyle. It aims to produce recommendations regarding physical activity and dietary intake for clinical practice. Although strong clinical evidence of the impact of lifestyle modifications is still lacking, practising healthy eating should be encouraged for the prevention of cancer, its occurrence or relapse. Physical activity is recommended to avoid excessive weight gain. For example, the beneficial effects on the risk of breast cancer could be achieved by walking half an hour per day. Three to five hours per week of moderate physical exercise therefore should be recommended for optimising the reduction of the risk of cancer. For most women, moderate to intense activity, such as heavy housework, brisk walking, or dancing, could provide an effective level of activity to keep reduce the risk of breast cancer.

Evaluation of the radiobiological impact of anatomic modifications during radiation therapy for head and neck cancer: can we simply summate the dose?

BACKGROUND AND PURPOSE: Adaptive strategies in radiotherapy (RT) require the knowledge of the total dose given to every organ of the body. Because of anatomical changes and setup errors non-rigid registration is necessary to map the different dose fractions to a common reference. This study evaluates practically if the accumulation of all of these registered dose fractions must take radiobiology into account in a classical clinical setting. MATERIALS AND METHODS: Ten patients with head and neck tumors treated by chemo-RT were used. Contrast-enhanced CT scans were acquired prior and during RT following delivery of mean doses of 14.2, 24.5, 35.0 and 44.9 Gy and the planned pre-treatment helical tomotherapy sinograms were applied on the per-treatment CTs to create a series of per-treatment dose distributions corresponding to each per-treatment CT image. In order to calculate the cumulative dose distribution, the per-treatment dose maps were non-rigidly deformed by using the deformation map computed by a non-rigid registration. The deformed dose maps were then summed in two ways: one while taking radiobiology into account and one without. These two strategies were compared using clinical surrogates in the target volumes (TV) and in surrounding organs at risk (OAR). RESULTS: The differences between the strategies, while statistically significant (p<0.05), are clinically irrelevant. In the OARs, the mean differences stay in the 0.01-0.07 Gy range for the total dose. In the targets, all mean differences stay in the 0.001-0.012 Gy range. However, some local high difference spots appear leading to punctual errors as high as 2.5 Gy. CONCLUSION: If using current radiotherapy practices and clinical recommendations based on dose surrogates computed globally on OARs and TVs, one does not need to take radiobiological effects into account while accumulating total dose as these lead to very small differences compared to a simple accumulation technique consisting of a linear sum of the dose fractions. However, care must be taken if other adaptive strategies, based on local rather than global information, are used.

Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation.

PURPOSE: Anatomic changes occur during radiation therapy (RT) for head and neck (H&N) tumors. This study aims at quantifying the volumetric and positional changes of gross tumor volumes (GTV), clinical target volumes (CTV), and organs at risk (OAR). Anatomic (CT) and functional (FDG-PET) imaging were used for the delineation of the GTVs. MATERIALS AND METHODS: Ten patients with H&N tumors treated by chemo-RT were used. Contrast-enhanced CT and FDG-PET were acquired prior and during RT following delivery of mean doses of 14.2, 24.5, 35.0, and 44.9 Gy. CT-based GTVs were manually delineated, and PET-based GTVs were segmented using a gradient-based segmentation method. Pre-treatment prophylactic dose CTVs were manually delineated on the pre-treatment CT using consistent and reproducible guidelines. Per-treatment prophylactic CTVs were obtained with an automatic re-contouring method based on deformable registration. For the therapeutic dose CTVs, a 5 mm margin was applied around the corresponding GTVs. OARs such as the parotid glands and the submandibular glands were manually delineated on the pre-treatment CT. OARs on the per-treatment CT were automatically delineated using the method used for prophylactic CTVs. The mean slopes of the relative change in volume over time and the mean displacements of the center of mass after 44.9 Gy were calculated for each volume. RESULTS: Regarding volumetric changes, CT-based and PET-based primary tumor GTVs decreased at a mean rate of 3.2% and 3.9%/treatment day (td), respectively; nodal GTVs decreased at a mean rate of 2.2%/td. This led to a corresponding decrease of the CT-based and PET-based therapeutic CTVs by 2.4% and 2.5%/td, respectively. CT- and PET-based prophylactic tumor CTVs decreased by an average of 0.7% and 0.5%/td, respectively. No difference in volume shrinkage was observed between CT- and PET-based volumes. The ipsilateral and contralateral parotid glands showed a mean decrease of 0.9% and 1.0%/td, respectively. The ipsilateral and contralateral submandibular glands shrank at a mean rate of 1.5% and 1.3%/td, respectively. Regarding positional changes, CT-based GTVs showed a lateral shift of 1.3 mm, PET-based GTVs a posterior shift of 3.4mm and the nodal GTVs a medial shift of 1.0 mm, translating into parallel shifts of the therapeutic CTVs. The ipsilateral prophylactic nodal CTV shifted medially by 1.8 mm. The ipsilateral parotid gland shifted medially by 3.4 mm. The ipsilateral submandibular gland showed a medial shift of 1.7 mm and a superior shift of 2.7 mm. The contralateral submandibular gland only showed a superior shift of 1.7 mm. CONCLUSIONS: Volumetric and positional changes in TVs and OARs were observed during concomitant chemo-RT suggesting that adaptive strategies, where patients are re-imaged and possibly re-planned during treatment, are worth evaluating.

Adaptive radiotherapy of head and neck cancer.

Intensity-modulated radiation therapy (IMRT) in head and neck (H&N) cancer has the capability to generate steep dose gradients, leading to an improved therapeutic index. IMRT plans are typically based on a pretreatment computed tomography scan that provides a snapshot of the patient's anatomy. Nevertheless, interfractional patient variations may occur because of setup error and anatomical modifications. Therefore, the accuracy of IMRT delivery for H&N cancer may be compromised during the treatment course, potentially affecting the therapeutic index. In this framework, adaptive radiotherapy is a potential solution, which consists of "the explicit inclusion of the temporal changes in anatomy during the imaging, planning, and delivery of radiotherapy." Adaptive radiotherapy has brought an additional dimension to the management of patients with H&N cancer and has the potential to counteract the effects of positioning errors and anatomical changes. This article reviews the causes and discusses potential solutions to circumvent the discrepancies between the planned dose and the actual dose received by patients treated for H&N malignancies.

Internal mammary lymph node irradiation contributes to heart dose in breast cancer.

We assessed the impact of internal mammary chain radiotherapy (IMC RT) to the radiation dose received by the heart in terms of heart dose-volume histogram (DVH). Thirty-six consecutive breast cancer patients presenting with indications for IMC RT were enrolled in a prospective study. The IMC was treated by a standard conformal RT technique (50 Gy). For each patient, a cardiac DVH was generated by taking into account the sole contribution of IMC RT. Cardiac HDV were compared according to breast cancer laterality and the type of previous surgical procedure, simple mastectomy or breast conservative therapy (BCT). The contribution of IMC RT to the heart dose was significantly greater for patients with left-sided versus right-sided tumors (13.8% and 12.8% for left-sided tumors versus 3.9% and 4.2% for right-sided tumors in the BCT group and the mastectomy group, respectively; p < 0.0001). There was no statistically significant difference in IMC contribution depending on the initial surgical procedure. IMC RT contributes to cardiac dose for both left-sided and right-sided breast cancers, although the relative contribution is greater in patients with left-sided tumors.

Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?

Endocrine therapy is often given together with postoperative radiotherapy in patients with breast cancer and positive hormone-receptor status. However, few experimental or clinical studies address the combined effects of hormone and radiation therapy. Preclinical models have shown changes in tumour cell kinetics with the addition of tamoxifen, and some show reduced tumour cell death with concurrent anti-oestrogen treatment and radiotherapy. Although data from in-vitro studies support the notion of antagonistic effects of concurrent tamoxifen and radiotherapy on tumour cells, in-vivo research suggests a synergistic effect that could be attributable to micro-environmental changes in tumour responsiveness to ionising radiation and hormone therapy. Retrospective studies suggest that in practical application, concurrent administration of tamoxifen with radiotherapy does not compromise local control but might increase toxicity. Preliminary results from simultaneous treatment with aromatase inhibitors and radiation indicate that this combination of endocrine and radiation therapy could enhance cytotoxicity and improve tumour response. Further studies are needed to clarify the physiological mechanisms activated by oestrogens, which will allow a more thorough understanding of the complex interactions between 17beta-oestradiol and P53/P21(WAF1/CIP1)/Rb pathways and of the interaction between endocrine therapy and radiotherapy.

Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.

BACKGROUND AND PURPOSE: Cardiac toxicity associated with anthracyclines and taxanes and/or radiotherapy (RT) can be life-threatening and can adversely affect quality of life. The aim was to evaluate treatment-related cardiac toxicity in breast cancer patients treated with doxorubicin/docetaxel/CMF sequential or combined regimens and RT. METHODS AND MATERIALS: From 1996 to 1998, 64 patients with stages II-III breast cancer were included in a pilot study that investigated the efficacy/feasibility of sequential and combined doxorubicin/docetaxel/CMF regimens. No patients had any cardiovascular history or ECG abnormalities. The same RT technique was performed in all patients. LVEF measurements were obtained at baseline, during, at the end of chemotherapy, at the end of radiotherapy and subsequently during the follow-up. A cardiac event was defined as a myocardial infraction or clinical evidence of congestive heart failure. RESULTS: Median age was 48 years (range 29-65 years). The median follow-up was 6 years. Significant drop in the post-treatment LVEF occurred in 21 patients (median decrease of 10%). Notwithstanding, all patients have preserved normal cardiac function and regained their initial LVEF value during follow-up. No cardiac events were reported. CONCLUSION: Sequential and combined doxorubicin/docetaxel/CMF regimens plus conventional RT in selected non high-risk cardiac patients are relatively safe without cardiac toxicity at mid-term follow-up.

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents.

Although conventional multimodality approaches allowed improvement in the prognosis of patients with cervix cancer, several tumors do not respond similarly to standard approaches. Recent advances in basic research and genomics have improved our understanding of the biologic basis of the tumor development and progression. Tumor profiling allows for more selective therapeutic strategies leading to the identification of biomarkers or indicators of treatment response and to increased clinical efficacy through development of targeted therapies. Several markers have been identified, that are involved in cellular proliferation, interaction with angiogenesis, extracellular matrice adhesion/invasion, apoptosis, cell cycle pathways and DNA repair mechanisms. In this report, molecular profiling of uterine cervix carcinoma were reviewed with a special focus on rationally designed target-based anticancer agents, in order to clarify and to summary the present state of art in these particular promising area in cervix cancer management.

The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.

Basic research in solid malignant tumours has led to a wealth of knowledge about this disease process and about novel ways to more effectively target our therapies. Laboratory research continues to identify novel therapeutic targets and moreover, clinical research is identifying effective new treatment regimens. Many preclinical studies in this area have targeted the epidermal growth factor receptor (EGFR) signalling pathway to increase radiosensitivity. The in vitro rationale for targeting EGFR and concurrent ionising radiation is well established, but to date, rare clinical data could provide proof-of-principle. Here we report all the different published clinical trials focusing on efficacy and toxicity in order to clarify and to summarise the present state-of-the-art of this particularly promising combination in solid tumour management.

Comparison of 12 deformable registration strategies in adaptive radiation therapy for the treatment of head and neck tumors.

BACKGROUND AND PURPOSE: Weight loss, tumor shrinkage, and tissue edema induce substantial modification of patient's anatomy during head and neck (HN) radiotherapy (RT) or chemo-radiotherapy. These modifications may impact on the dose distribution to both target volumes (TVs) and organs at risk (OARs). Adaptive radiotherapy (ART) where patients are re-imaged and re-planned several times during the treatment is a possible strategy to improve treatment delivery. It however requires the use of specific deformable registration (DR) algorithms that requires proper validation on a clinical material. MATERIALS AND METHODS: Twelve voxel-based DR strategies were compared with a dataset of 5 patients imaged with computed tomography (CT) before and once during RT (on average after a mean dose of 36.8Gy): level-set (LS), level-set implemented in multi-resolution (LS(MR)), Demons' algorithm implemented in multi-resolution (D(MR)), D(MR) followed by LS (D(MR)-LS), fast free-form deformable registration via calculus of variations (F3CV) and F3CV followed by LS (F3CV-LS). The use of an edge-preserving denoising filter called "local M-smoothers" applied to the registered images and combined to all the aforesaid strategies was also tested (fLS, fLS(MR), fD(MR), fD(MR)-LS, fF3CV, fF3CV-LS). All these strategies were compared to a rigid registration based on mutual information (MI, fMI). Chronological and anti-chronological registrations were also studied. The various DR strategies were evaluated using a volume-based criterion (i.e. Dice similarity index, DSI) and a voxel-intensity criterion (i.e. correlation coefficient, CC) on a total of 18 different manually contoured volumes. RESULTS: For the DSI analysis, the best three strategies were D(MR), fD(MR)-LS, and fD(MR), with the median values of 0.86, 0.85 and 0.85, respectively; corresponding inter-quartile range (IQR) reached 9.6%, 10% and 10.2%. For the CC analysis, the best three strategies were fD(MR)-LS, D(MR)-LS and D(MR) with the median values of 0.97, 0.96 and 0.94, respectively; corresponding IQR reached 11%, 9% and 15%. Concerning the time-sequence analysis, the anti-chronological registration (all deformable strategies pooled) showed a better median DSI value (0.84 vs 0.83, p<0.001) and IQR (11.2% vs 12.4%). For CC, the anti-chronological registration (all deformable strategies pooled) had a slightly lower median value (0.91 vs 0.912, p<0.001) but a better IQR (16.4% vs 21%). CONCLUSIONS: The use of fD(MR)-LS is a good registration strategy for HN-ART as it is the best compromise in terms of median and IQR for both DSI and CC. Even though less robust in terms of CC, D(MR) is a good alternative. None of the time-sequence appears superior.

Is radiologic placement of an arm port mandatory in oncology patients?: analysis of a large bi-institutional experience.

BACKGROUND: The objective of the current study was 2-fold: to evaluate a radiologically placed percutaneous arm port device (PRAPD) in a large series of 1000 consecutive cancer patients undergoing chemotherapy (in terms of safety, efficacy, complications, and quality of life [QoL]) and to propose future recommendations. METHODS: From 1998 to August 2002, all patients who had cancer required chemotherapy underwent insertion of a PRAPD and were prospectively included. All patients were followed for technical feasibility, overall device-related complications, and QoL. RESULTS: Technical failures (6.3%) were caused by the inability to perform an arm venogram in 22 patients or to catheterize the brachial vein in 41 patients. Septic complications (3.2%) included septicemia (n = 7 patients), catheter sepsis (n = 9 patients), and febrile neutropenia (n = 16 patients). Mechanical complications (4%) included a twisted port (n = 2 patients), extravasation (n = 7 patients), catheter leaks (n = 7 patients), port obstruction (n = 7 patients), skin dehiscence of the port (n = 11 patients), catheter rupture and occlusion (n = 5 patients), and median nerve compression (n = 1 patient). Central venous thrombosis occurred in 12 patients (1.2%), and arm phlebitis occurred in 7 patients (0.7%). Procedure-related death occurred in 0.4%. Early port removal was performed in 5.3% of patients. Good QoL was reported at port removal. CONCLUSIONS: The PRAPD was found to be safe, effective, and well tolerated in oncology patients. PRAPD could be recommended in selected patients instead of a surgical port device.

Estrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53.

PURPOSE: Sequential administration of radiotherapy and endocrine therapy is considered to be a standard adjuvant treatment of breast cancer. Recent clinical reports suggest that radiotherapy could be more efficient in association with endocrine therapy. The aim of this study was to evaluate the estrogen effects on irradiated breast cancer cells (IR-cells). METHODS AND MATERIALS: Using functional genomic analysis, we examined the effects of 17-beta-estradiol (E(2), a natural estrogen) on MCF-7 breast cancer cells. RESULTS: Our results showed that E(2) sustained the growth of IR-cells. Specifically, estrogens prevented cell cycle blockade induced by gamma-rays, and no modification of apoptotic rate was detected. In IR-cells we observed the induction of genes involved in premature senescence and cell cycle progression and investigated the effects of E(2) on the p53/p21(waf1/cip1)/Rb pathways. We found that E(2) did not affect p53 activation but it decreased cyclin E binding to p21(waf1/cip1) and sustained downstream Rb hyperphosphorylation by functional inactivation of p21(waf1/cip1). We suggest that Rb inactivation could decrease senescence and allow cell cycle progression in IR-cells. CONCLUSION: These results may help to elucidate the molecular mechanism underlying the maintenance of breast cancer cell growth by E(2) after irradiation-induced damage. They also offer clinicians a rational basis for the sequential administration of ionizing radiation and endocrine therapies.

Metabolic functional imaging for tumor radiosensitivity monitoring.

Assessing tumor radiosensitivity before and during radiation therapy can be a crucial element in decision-making with regard to treatment. However, no known non-invasive test is available at present, which allows for a reliable evaluation of the radiosensitivity of a tissue subjected to radiotherapy. Among tests being evaluated, positron emission tomography (PET) is considered to be a promising method. The purpose of this review is to identify the tests and research paths that have recently been explored for the evaluation of tumor response to treatment after isotopic labeling revealed by nuclear imaging. The majority of the explored methodologies are based on the indirect evaluation of the radiosensitivity by cell proliferation or apoptosis, tissue oxygenation or hypoxia, intrinsic radiosensitivity of clonogenic cells, tumor metabolism and angiogenesis. The development of such methods would permit the adoption of a therapeutic regimen with respect to a given radiosensitivity of a tissue. Therefore, a given therapeutic strategy could be readjusted (by associating, for instance, a radiosensitizer of hypoxic cells) or even modified if it proved to be inadequate or when it presents an unfavorable cost-effectiveness ratio. We present here a critical review of the radiotracers revealed by nuclear imaging that are developed for radiosensitivity monitoring.

Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network.

PURPOSE: The aim of this study was to assess the outcome in patients with cerebellar glioblastoma (GBM) treated in 15 institutions of the Rare Cancer Network. METHODS AND MATERIALS: Data from a series of 45 adult patients with cerebellar GBM were collected in a retrospective multicenter study. Median age was 50.3 years. Brainstem invasion was observed in 9 (20%) patients. Radiotherapy (RT) was administered to 36 patients (with concomitant chemotherapy, 7 patients). Adjuvant chemotherapy after RT was administered in 8 patients. Median RT dose was 59.4 Gy. Median follow-up was 7.2 months (range, 3.4-39.0). RESULTS: The 1-year and 2-year actuarial overall survival rate was 37.8% and 14.7%, respectively, and was significantly influenced by salvage treatment (p = 0.048), tumor volume (p = 0.044), extent of neurosurgical resection (p = 0.019), brainstem invasion (p = 0.0013), additional treatment after surgery (p < 0.001), and completion of the initial treatment (p < 0.001) on univariate analysis. All patients experienced local progression: 8 and 22 had progression with and without a distant failure, respectively. The 1- and 2-year actuarial progression free survival was 25% and 10.7%, respectively, and was significantly influenced by brainstem invasion (p = 0.002), additional treatment after surgery (p = 0.0016), and completion of the initial treatment (p < 0.001). On multivariate analysis, survival was negatively influenced by the extent of surgery (p = 0.03) and brainstem invasion (p = 0.02). CONCLUSIONS: In this multicenter retrospective study, the observed pattern of failure was local in all cases, but approximately 1 patient of 4 presented with an extracerebellar component. Brainstem invasion was observed in a substantial number of patients and was an adverse prognostic factor.

[Metastasis of a lumbosacral ependymoma with very long disease-free survival: a case report and review of the literature]. / Métastase d'un épendymome lombosacré avec très long intervalle libre: cas clinique et revue de la littérature.

Ependymoma is rare glial tumour of the central nervous system and is considered to be low-grade. The lumbosacral location of spinal ependymoma is the most common. Prognosis of ependymomas is dependent on tumour location, histological subtype and differentiation, extent of the tumour and of the completeness of the surgical resection. One of the characteristics of this kind of tumour is to present the possibility of a seeding of the entire cerebrospinal axis, by the way of cerebrospinal liquid. We describe the case of a young male patient operated by incomplete resection of a lumbar ependymoma. Six months later, the patient's symptoms reappeared and an external radiotherapy at curative doses and chemotherapy were delivered. Evolution of the remaining tumour was diagnosed 6 years after at the primary site and operated by large incomplete resection. A second session of radiotherapy was therefore administered. Twenty-four years after this episode, cervical pain and gait troubles appear. Complete imaging study concluded to a cervical extramedullary intradural tumour and to the persistence of the primary lumbosacral tumour. Macroscopical complete resection of the cervical tumour was performed and pathological findings concluded to a metastasis of his lumbar ependymoma. External radiotherapy was delivered on this site with a total dose of 50 Gy. Eight years after this episode, the patient is alive without evidence of distant disease. The primary lumbosacral ependymoma is stable. Ependymomas are often recurrent at the primary site, but can seed on the entire cerebrospinal axis. Awareness of such aberrant tumoral behaviour, even after such a long disease free interval, may warrant more careful follow-up of patients with this diagnosis.

Radiation recall: a well recognized but neglected phenomenon.

INTRODUCTION: Radiation recall is an inflammatory skin reaction at a previously irradiated field subsequent to the administration of a variety of pharmacologic agents. Although skin has been the major site of radiation recall toxicity, instances involving other organ have been reported. MATERIALS AND METHODS: Data for this review were identified by searches of Medline and Cancerlit. The search terms "radiation", "recall", and "toxicity" were used. References identified from within retrieved articles were also used. There was no limitation on year of publication and no abstract forms were included. Only articles published in English were taken into consideration. RESULTS: Idiosyncratic drug hypersensitivity phenomenon is a recent hypothesis which correlates best with the available facts at this moment. The phenomenon may occur days to years after radiotherapy has been completed. The majority of the drugs commonly used in cancer therapy have been involved in the radiation recall phenomenon. A mixed non-specific inflammatory infiltrate seems to be the common histopathologic criteria in previous published reports. Universally, corticosteroids or the use of non-steroidal anti-inflammatory agents, in conjunction with withdrawal of the offending agent, produce prompt improvement. CONCLUSION: We propose to collect all future radiation recall phenomenon in a Rare Cancer Network database in order to augment our understanding of this rare reaction.